Clinical Pharmacokinetics of Teicoplanin
Tóm tắt
The glycopeptide antibacterial teicoplanin has become increasingly popular in the last decade with the rise in infections related to methicillin-resistant Staphylococcus aureus. Teicoplanin has 6 major and 4 minor components. It is predominantly (90%) bound to plasma proteins. Of the several methods available to measure concentrations in serum, fluorescence polarisation immunoassay has high reliability and specificity. Teicoplanin is not absorbed orally, but intravenous and intramuscular administration are well tolerated. Teicoplanin is eliminated predominantly by the kidneys and only 2 to 3% of an intravenously administered dose is metabolised. Total clearance is 11 ml/h/kg. Steady state is reached only slowly, 93% after 14 days of repeated administration. Elimination is triexponential, with half-lives of 0.4 to 1.0, 9.7 to 15.4 and 83 to 168 hours. Volumes of distribution are 0.07 to 0.11 (initial phase), 1.3 to 1.5 (distribution phase) and 0.9 to 1.6 (steady state) L/kg. A standard dosage regimen of 6 mg/kg every 12 hours for 3 doses, then daily, will produce therapeutic serum concentrations of ≥10 mg/L in most patients. Higher dosages may be required in certain patients, for example intravenous drug abusers or those with burns, because of unpredictable clearance. Concentrations in bone reach 7 mg/L at 12 hours after a dose of teicoplanin 6 mg/kg, but reach only 3.5 mg/L in the cartilage. Doses of 10 mg/kg are necessary to achieve adequate bone concentrations. There is little penetration into cerebrospinal fluid or the aqueous or vitreous humour. In fat, concentrations may be subtherapeutic (0.5 to 5 mg/L) after a dose of 400mg. A single prophylactic dose of 12 mg/kg is sufficient to maintain therapeutic concentrations during cardiopulmonary bypass or burns surgery. High loading doses reduce the delay to attaining therapeutic concentrations. Premature neonates require a loading dose of 15 mg/kg and a maintenance dosage of 8 mg/kg daily to ensure therapeutic serum concentrations. Children need loading with 10 mg/kg every 12 hours for 3 doses followed by maintenance with 10 mg/kg/day. Clearance is reduced predictably in renal failure, and dosage adjustments can be based on the ratio of impaired clearance to normal clearance. In patients on haemodialysis, 3 loading doses of 6 mg/kg at 12-hour intervals followed by maintenance doses every 72 hours produced trough plasma concentrations of 8 mg/L in most patients at 48 hours. The monitoring of serum concentrations is not necessary to avoid toxicity, but can be helpful in certain patient groups to ensure therapeutic concentrations are present, especially in those not responding to treatment.
Tài liệu tham khảo
Rowland M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 1990; 18: 184–209.
Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans. Antimicrob Agents Chemother 1992; 36: 1744–9.
Borghi A, Duncan E, Zerilli LF, et al. Factors affecting the normal and branched chain acyl moieties of teicoplanin components produced by Actinoplanes teichomyceticus. J Gen Microbiol 1991; 137: 587–92.
Bernareggi A, Borgonovi M, Del Favero A, et al. Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers. Eur J Drug Metab Pharmacokinet 1991; Spec. No. 3: 256–60.
Tounian P, Jehl F, Pauliat S, et al. Stability and compatibility of teicoplanin in parenteral nutrition solutions used in pediatrics. Clin Nutr 1999; 18: 159–65.
Bossi A, Righetti PG, Riva E, et al. Purification of glycopeptide antibiotics by isoelectric focusing in multicompartment electrolyzers with immobile membranes. Electrophoresis 1996; 17: 1234–41.
Taylor RB, Reid RG, Gould IM. Determination of teicoplanin in plasma using microbore high-performance liquid chromatography and injection-generated gradients. J Chromatography 1991; 563: 451–7.
McMullin CM, White LO, MacGowan AP, et al. Assay of serum teicoplanin concentrations in clinical specimens: a comparison of isocratic high performance liquid chromatography with polarisation fluoroimmunoassay and bioassay. J Antimicrob Chemother 1994; 34: 425–9.
Cox H, Whitby M, Nimmo G, et al. Evaluation of a novel fluorescence polarization immunoassay for teicoplanin. Antimicrob Agents Chemother 1993; 37: 1924–6.
Rybak MJ, Bailey EM, Reddy VN. Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrob Agents Chemother 1991; 35: 1586–90.
Mastin S, Buck RL, Mueggler PA. Performance of a fluorescence polarization immunoassay for teicoplanin in serum. Diagn Microbiol Infect Dis 1993; 16: 17–24.
White LO, McMullin C, Davis AJ, et al. The quality of clinical serum teicoplanin assays: an experimental European EQA distribution. J Antimicrob Chemother 1996; 38: 701–6.
Data on file, Hoechst Marion Roussell, 1997.
Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhoea. Clin Infect Dis 1996; 22: 813–8.
De Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhoea. Antimicrob Agents Chemother 1992; 36: 2192–6.
Antony KK, Lewis EW, Kenny MT, et al. Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans. J Pharm Sci 1991; 80: 605–7.
Del Favero A, Patoia L, Rosina R, et al. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob Ag Chemother 1991; 35: 2551–7.
Steer JA, Papini RPG, Wilson APR, et al. Teicoplanin versus flucloxacillin in the treatment of infection following burns. J Antimicrob Chemother 1997; 39: 383–92.
Martin C, Bourget P, Alaya M, et al. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chem-other 1997; 41: 1150–5.
MacGowan AP, McMullin CM, White LO, et al. Serum monitoring of teicoplanin. J Antimicrob Chemother 1992; 30: 399–402.
Bantar C, Durlach R, Nicola F, et al. Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 1999; 43: 737–40.
Lenders H, Walliser D, Schumann K. Teicoplanin-spiegel in tonsillen-, schleimhaut-, knorpel- und knochengewebe. Fortschr Antimikrob Antineoplast Chemother 1991; 10–2: 119–21.
Holzapfel L, Ract C, Jeannot T, et al. Penetration of teicoplanin into the sinuses of patients with nosocomial sinusitis [abstract]. 14th Interdisciplinary Meeting on Anti-infectious Chemotherapy; 1994 Dec 1–2; Paris. 243.
Nehrer S, Thalhammer F, Schwameis E, et al. Teicoplanin in the prevention of infection in total hip replacement. Arch Orthop Trauma Surg 1998; 118: 32–6.
De Lalla F, Novelli A, Pellizzer G, et al. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1993; 37: 2693–8.
Isringhaus H, Lang E, Witte PU, et al. Tolerability and pharmacokinetics of teicoplanin in patients undergoing heart surgery: preliminary results. Int J Antimicrob Agents 1992; 1 Suppl. 1: S31–6.
Miglioli PA, Merlo F, Fabbri A, et al. Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio-pulmonary bypass surgery. J Antimicrob Chemother 1997; 39: 229–33.
Frank UK, Schmidt-Eisenlohr E, Mlangeni D, et al. Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery. Antimicrob Agents Chemother 1997; 41: 2559–61.
Exner K, Lang E, Borsche A, et al. Efficacy, tolerability and pharmacokinetics of teicoplanin in patients undergoing breast surgery. Eur J Surg 1992; Suppl. 567: 33–8.
Cruciani M, Navarra A, Di Perri G, et al. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis 1992; 15: 285–9.
Briggs MC, McDonald P, Bourke R, et al. Intravitreal penetration of teicoplanin. Eye 1998; 12: 252–5.
De Lalla F, Alegente G, Zaffaina A, et al. Penetration of teicoplanin into aqueous humor. 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2; Stockholm, 389.
Antoniadou A, Vougioukas N, Kavouklis E, et al. Penetration of teicoplanin into human aqueous humor after subconjunctival and IV administration [abstract 248]. Clin Infect Dis 1998; 27: 967.
Steer J, Papini R, Wilson APR, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 37: 545–53.
Breux JP, Bouquet S, Breton I, et al. High concentrations of teicoplanin in cardiac vegetations in human endocarditis [abstract]. 14th Interdisciplinary Meeting on Anti-Infectious Chemotherapy; 1994 Dec 1–2; Paris, 243.
Smithers JA, Kulmala HK, Thompson GA, et al. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers. Antimicrob Agents Chem-other 1992; 36: 115–20.
Niu W, Neu HC. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin and daptomycin. Antimicrob Agents Chemother 1991; 35: 998–1000.
Thompson GA, Smithers JA, Kenny MT, et al. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy volunteers. Biopharm Drug Dispos 1992; 13: 213–20.
Wilson APR, Grüneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4 Suppl. 1: 1–30.
Harding I, MacGowan AP, White LO, et al. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000; 45: 835–41.
MacGowan AP, White LO, Reeves DS, et al. A retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother 1998; 2: 197–208.
Reed MD, Yamashita TS, Myers CM, et al. The pharmacokinetics of teicoplanin in infants and children. J Antimicrob Chem-other 1997 39: 789–96.
Rybak MJ, Lerner SA, Levine DP, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991; 35: 696–700.
Chow AW, Jewesson PJ, Kureishi A, et al. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol 1993; 51 Suppl. 54: 18–24.
Lortholary O, Tod M, Rizzo N, et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996; 40: 1242–7.
Sauvageon-Martre H, Vermerie N, Sauvageon X, et al. Teicoplanin pharmacokinetics in intensive care patients: comparison of two loading doses. 4th International Marion Merrell Dow Inc Symposium on Gram-positive infection; 1991; Lake Como, Italy. 11.
Kacet N, Dubos JP, Roussel-Delvallez M, et al. Teicoplanin and amikacin in neonates with staphylococcal infection. Pediatr Infect Dis J 1993; 12 Suppl.: 10–3.
Degraeuwe PL, Beuman GH, van Tiel FH, et al. Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis. Biol Neonate 1998; 73: 287–94.
Dufort G, Ventura C, Olive T, et al. Teicoplanin pharmacokinetics in pediatric patients. Pediatr Infect Dis J 1996; 15: 494–8.
Smithers JA, Thompson GA, Kenny MT, et al. Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg−1. Biopharm Drug Dispos 1992; 13: 571–81.
Hoffler D, Koeppe P, Nauman E, et al. Pharmacokinetics of teicoplanin in hemodialysis patients. Infection 1991; 19: 324–7.
Wolter K, Claus M, Wagner K, et al. Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis. Clin Nephrol 1994; 42: 389–97.
Thalhammer F, Rosenkranz AR, Burgmann H, et al. Single dose pharmacokinetics of teicoplanin during haemodialysis therapy using high-flux polysulfone membranes. Wien Klin Wochenschr 1997; 109/10: 362–5.
Hillaire-Buys D, Peyriere H, Lobjoie E, et al. Influence of arterio-venous haemofiltration on teicoplanin elimination. Br J Clin Pharmacol 1995; 40: 95–7.
Mercatello A, Jaber K, Hillaire-Buys D, et al. Concentrations of teicoplanin in the serum of adults with end stage chronic renal failure undergoing treatment for infection. J Antimicrob Chemother 1996; 37: 1017–21.
Menth M, Fiegel P. Elimination of teicoplanin via different dialysis membranes: in-vitro investigation. Int J Antimicrob Agents 1992; 1 Suppl. 1: 45–8.
Kroh UF, Dinges GK, Lukasewitz P, et al. Elimination of drugs by the new polyamide hemofilter FH77H during various in vitro conditions. Blood Purif 1998; 16: 49–56.
Finch RG, Holliday AP, Innes A, et al. Pharmacokinetic behaviour of intraperitoneal teicoplanin during treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1996; 40: 1971–2.
Wilson APR. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998; 10: 143–52.
Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209–22.
Fanos V, Mussap M, Khoory BJ, et al. Renal tolerability of teicoplanin in a case of neonatal overdose. J Chemother 1998; 10: 381–4.
Fan-Havard P, Koshy Z, Bais RM, et al. Effect of morphine or phenobarbital on teicoplanin elimination pharmacokinetics. J Antimicrob Chemother 1993; 32: 101–8.
Angrisani M, Cazzola M, Loffreda A, et al. Clinical pharmacokinetics of teicoplanin and aminophylline during cotreatment with both medicaments. Int J Clin Pharmacol Res 1992; 12: 165–71.
Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacother 1993; 27: 704–7.
MacGowan AP. Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998; 20: 473–7.
Graninger W, Wenisch C, Wiesinger E, et al. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 643–7.
Graninger W, Wenisch C, Wiesinger E. Teicoplanin thrice weekly for the therapy of infective endocarditis [abstract 1203]. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26–30; Vienna. 234.
De Lalla F, Viola R, Pellizzer G, et al. Regional prophylaxis with teicoplanin in monolateral or bilateral total knee replacement: an openstudy. Antimicrob Agents Chemother 2000; 44: 316–9.